Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

ing diseases. In addition to a recently completed Phase IIIb study in malignant mesothelioma, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

ALFACELL CORPORATION

Condensed Statements of Operations

Three-Months Ended Fiscal Year Ended

July 31 July 31

2008 2007 2008
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... LANSING, Mich., July 22, 2014  Neogen Corporation (NASDAQ: ... its 2014 fiscal year, which ended May 31, increased ... net income was $28,158,000, compared to the prior year,s ... 30, 2013, earnings per share in the current year ... revenues and net income for the 2014 fiscal year ...
(Date:7/22/2014)... , July 22, 2014 Hussey Copper ... MD-Cu 29 antimicrobial copper announces Pullman Regional Hospital,s ... first EPA-registered antimicrobial solid touch surface, at a nominal ... of MRSA, E-coli and other bacteria within 2 hours of ... protecting against bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... July 22, 2014  United Therapeutics Corporation (NASDAQ: ... will release its second quarter 2014 financial results ... United Therapeutics will host a half-hour ... a.m. Eastern Time.  The teleconference is accessible by ... rebroadcast of the teleconference will be available for ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Williams ... those who have recognized that the greatest health care ... far too often needlessly deadly while trying to serve ... of quasi-experts seeking to transform an enormous system that ... Dr. Williams, in his continuing series of Open Letters ...
Breaking Biology Technology:Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2
... in Key Markets, Differentiated Product Offerings and ... Performance, CARY, N.C., Jan. 10 ... significant milestone with the signing of its ... additional customers during the,second half of 2007. ...
... LONDON, January 10 Amarin Corporation plc,(NASDAQ: AMRN ... and ethical approvals to commence a Phase IIa trial ... The Phase IIa trial will be a randomized, ... AAMI who,will be randomized to receive 1, 2 or ...
... Essilor International,s US subsidiary, has strengthened its,prescription laboratory ... Interstate Optical Co., one of the country,s five ... and,Indianapolis, Indiana serve eye care professionals in 32 ... and 210 employees., Present for more than ...
Cached Biology Technology:SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 2SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 3SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations 4Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 2Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 3Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment 4
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST), ... dramatically improved technique for analyzing biological cells and ... new NIST technique is an advanced form of ... that delivers signals that are 10,000 times stronger ... times stronger than obtained from comparable "coherent Raman" ...
(Date:7/22/2014)... N.C. In a cost-effectiveness analysis of commercial diet ... drug Qsymia showed the best value for the money. ... but was also the most expensive option tested, according ... Medical School. , The findings, published in the June ... information on the health and weight-loss benefits per dollar ...
(Date:7/22/2014)... Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant Professor of ... Orleans School of Nursing, contributed samples used in ... associated with schizophrenia and also suggesting a possible ... study, Biological insights from 108 schizophrenia-associated genetic loci, ... Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... Bio-Technology Group Co., Inc. (OTC Bulletin Board: ... leading developer, manufacturer and marketer of Traditional Chinese ... other health and nutritional products in the People,s ... its private placement offering for aggregate gross proceeds ...
... In order for medical students to ultimately provide quality patient ... teach physiology, one of the core disciplines of medicine, according ... Journal of the American College of Radiology ( www.jacr.org ... systems. "It is vital that medical schools provide ...
... Avantra Biosciences (Avantra) today announced the selection ... test site for Avantra,s new biomarker quantitation platform. ... has created an automated multiplex immunoassay system to ... patient characteristics, and drug responses. The new Q400 ...
Cached Biology News:Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3Avantra Biosciences teams with TGen Drug Development to assist pharma 2
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-DM 2 x 109 cells...
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... Rabbit Antibody to CRF ... with the ovine CRF sequence ... Cells and fibres are found ... of rat brain in colchicine ...
Biology Products: